Literature DB >> 25247618

How we investigate drug-induced immune hemolytic anemia.

Regina M Leger1, Patricia A Arndt2, George Garratty3.   

Abstract

Drugs are a rare cause of immune hemolytic anemia, but an investigation for a drug antibody may be warranted if a patient has definitive evidence of immune hemolysis, other more common causes of hemolysis have been excluded, and there is a good temporal relationship between the administration of a drug and the hemolytic event. Drug antibodies are either drug-dependent (require drug to be in the test system) or drug-independent (reactive without drug present in the test). Drug-dependent antibodies are investigated by testing drug-treated red blood cells (RBCs) or by testing RBCs in the presence of a solution of drug. Drug-independent antibodies are serologically indistinct from idiopathic warm autoantibodies and cannot be defined or excluded by serologic testing. Nonimmunologic protein adsorption, caused by some drugs, is independent of antibody production but may also cause immune hemolytic anemia. Serologic methods for testing for drug antibodies are presented, and observations from more than 30 years of this laboratory's experience are discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25247618

Source DB:  PubMed          Journal:  Immunohematology        ISSN: 0894-203X


  5 in total

Review 1.  Non-chemotherapy drug-induced neutropenia: key points to manage the challenges.

Authors:  Brian R Curtis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

2.  Case Report: First Case of Cefotaxime-Sulbactam-Induced Acute Intravascular Hemolysis in a Newborn With ABO Blood Type Incompatibility by the Mechanism of Non-Immunologic Protein Adsorption.

Authors:  Yuanjun Wu; Yong Wu; Yong Yang; Baochan Chen; Jianqun Li; Ganping Guo; Fu Xiong
Journal:  Front Immunol       Date:  2021-12-22       Impact factor: 7.561

Review 3.  Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature.

Authors:  Hans Benno Leicht; Elke Weinig; Beate Mayer; Johannes Viebahn; Andreas Geier; Monika Rau
Journal:  BMC Pharmacol Toxicol       Date:  2018-10-25       Impact factor: 2.483

4.  COVID-19 and the Coombs test.

Authors:  Jeanne E Hendrickson; Christopher A Tormey
Journal:  Blood       Date:  2020-08-06       Impact factor: 22.113

5.  An Uncommon Incidence of Drug-Induced Immune Hemolytic Anemia Secondary to Ceftriaxone.

Authors:  Aishwarya Sharma; Shannon Chamberlain; Devendranath Mannuru; Abhishek Matta
Journal:  Cureus       Date:  2021-12-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.